Automated Flow Cytometry Enables Standardized, Rapid Profiling of Cellular Starting Material for Predictable, Potent Products
Description: Cell therapy drug product potency is sensitive to the quality and composition of the starting material, including leukapheresis and cryopreservation conditions and biological variability. Understanding cellular attributes of this material allows manufacturers to establish appropriate potency metrics and predict functionality of the final product. The Accellix automated flow cytometry platform harmonizes results across operators and sites, providing a meaningful step forward in standardization of flow cytometry and linking starting material assessment with predictable, potent cell therapy products. The automated sample preparation and analysis workflow will be described, and results from leukapheresis samples will be shared.
Provide the following information and we’ll email you a copy of the poster:
*Required field
